Charles Schwab Investment Management Inc. Takes $676,000 Position in Sionna Therapeutics, Inc. $SION

Charles Schwab Investment Management Inc. acquired a new stake in shares of Sionna Therapeutics, Inc. (NASDAQ:SION) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 64,644 shares of the company’s stock, valued at approximately $676,000. Charles Schwab Investment Management Inc. owned about 0.15% of Sionna Therapeutics at the end of the most recent quarter.

Separately, Jennison Associates LLC bought a new position in shares of Sionna Therapeutics during the first quarter valued at about $8,995,000.

Analyst Ratings Changes

Separately, Wall Street Zen raised shares of Sionna Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 16th. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Sionna Therapeutics presently has an average rating of “Buy” and an average price target of $38.50.

Insiders Place Their Bets

In other Sionna Therapeutics news, CFO Elena Ridloff sold 16,098 shares of the company’s stock in a transaction dated Thursday, August 28th. The shares were sold at an average price of $25.97, for a total value of $418,065.06. Following the sale, the chief financial officer owned 48,116 shares in the company, valued at approximately $1,249,572.52. This represents a 25.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Michael Cloonan sold 7,426 shares of the company’s stock in a transaction dated Wednesday, August 27th. The stock was sold at an average price of $25.01, for a total transaction of $185,724.26. Following the completion of the sale, the chief executive officer owned 547,343 shares in the company, valued at approximately $13,689,048.43. This trade represents a 1.34% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 48,416 shares of company stock worth $1,226,229. 3.90% of the stock is currently owned by company insiders.

Sionna Therapeutics Stock Performance

Shares of SION opened at $25.39 on Wednesday. Sionna Therapeutics, Inc. has a fifty-two week low of $7.26 and a fifty-two week high of $26.50. The firm’s 50-day simple moving average is $20.08 and its two-hundred day simple moving average is $15.82.

Sionna Therapeutics (NASDAQ:SION) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.27.

About Sionna Therapeutics

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.